The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - VBI Vaccines
Leadership - VBI Vaccines
Stock and Other Ownership Interests - VBI Vaccines
Research Funding - VBI Vaccines
Patents, Royalties, Other Intellectual Property - VBI Vaccines
Travel, Accommodations, Expenses - VBI Vaccines
Evaluation of GM-CSF and AS01B adjuvants in a phase I/IIa trial of a therapeutic CMV vaccine (VBI-1901) against recurrent glioblastoma (GBM).
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; Deciphera; deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
David A. Reardon
Honoraria - Advantagene; Agenus; Bayer; Bristol-Myers Squibb; DelMar Pharmaceuticals; EMD Serono; Imvax; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical
Consulting or Advisory Role - Advantagene; Agenus; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; EMD Serono; Imvax; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Omniox
 
Deborah Anne Forst
Stock and Other Ownership Interests - Lilly
 
Eudocia Quant Lee
Honoraria - Medlink
Consulting or Advisory Role - Prime Oncology
Patents, Royalties, Other Intellectual Property - Royalties from Wolter Kluwer for Up to Date, Inc
 
Fabio Massaiti Iwamoto
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Guidepoint Global; Merck; Novocure; Regeneron; tocagen
Speakers' Bureau - Prime Oncology
Research Funding - Bristol-Myers Squibb; Celldex; FORMA Therapeutics; Merck; Northwest Biotherapeutics; tocagen
Travel, Accommodations, Expenses - Oncoceutics
(OPTIONAL) Uncompensated Relationships - Northwest Biotherapeutics
 
Francisco Diaz-Mitoma
No Relationships to Disclose
 
David E Anderson
Employment - VBI Vaccines
Leadership - VBI Vaccines
Stock and Other Ownership Interests - VBI Vaccines
Patents, Royalties, Other Intellectual Property - As Chief Scientific Officer at VBI Vaccines, I am an inventor on much of the company's patent, including that of VBI-1901 (the subject of submitted abstract).
Travel, Accommodations, Expenses - VBI Vaccines
 
Andrew B. Lassman
Honoraria - Abbott Molecular
Consulting or Advisory Role - Bayer; BioClinica; Elsevier; FORMA Therapeutics; Karyopharm Therapeutics; Novocure; Orbus Therapeutics; QED Therapeutics; Sapience Therapeutics
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agios (Inst); Bayer (Inst); BeiGene (Inst); BMS (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); RTOG Foundation (Inst); VBI Vaccines (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Abbott Molecular; AbbVie; Bayer; BioClinica; FORMA Therapeutics; Karyopharm Therapeutics; Novartis; Orbus Therapeutics; Pfizer; QED Therapeutics